Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 7, 2008

Primary Completion Date

February 4, 2009

Study Completion Date

February 4, 2009

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

CE-224,535

500 mg po BID

DRUG

Placebo

no active ingredient

Trial Locations (27)

15006

Complexo Hospitalario Universitario A Coruña, A Coruña

15705

Hospital Nuestra Señora de La Esperanza, Santiago de Compostela

21702

The Arthritis and Osteoporosis Center of Maryland, Frederick

28007

Hospital General Universitario Gregorio Marañon, Madrid

32713

Omega Research Consultants LLC, DeBary

32746

Florida Arthritis Center, Lake Mary

33614

Tampa Medical Group, PA, Tampa

45242

New Horizons Clinical Research, Cincinnati

46123

American Health Network, Avon

65203

University Physicians, Columbia

65212

University of Missouri-Columbia, Columbia

70115

Best Clinical Trials, LLC (Administrative Only), New Orleans

George Stanley Walker, MD, New Orleans

Majid Abdul Jawad, MD, New Orleans

85202

Arizona Arthritis & Rheumatology Associates, P.C., Mesa

89502

Arthritis Center of Reno, Reno

7530206

Clínica Santa María, Sección Reumatología, Providencia

99204-2336

Arthritis Northwest, Spokane

470 01

Revmatologicka ambulance, Česká Lípa

128 50

Revmatologicky ustav, Prague

140 00

Revmatologicka ambulance, Prague

03300

Investigadores Clinicos Asociados, México

31-501

Krakowskie Centrum Medyczne NZOZ, Krakow

60-356

Zaklad Reumatologii i Immunologii Klinicznej, Poznan

61-545

Oddzial Reumatologiczno-Rehabilitacyjny IIR Ortopedyczno-Rehabilitacyjny, Poznan

400-711

Inha University Hospital, Medicine/Rheumatology, Incheon

602-739

Pusan National University Hospital, Rheumatology, Internal Medicine, Pusan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY